Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the impact of herpes zoster vaccine on the incidence of herpes zoster and survival in lung cancer patients, and to explore its preventive effect and safety.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vaccination group | Lung cancer patients receive herpes zoster vaccine |
| |
| Unvaccinated group | Lung cancer patients have not received herpes zoster vaccine |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| herpes zoster vaccine | Biological | Receive the herpes zoster vaccine; Do not receive the herpes zoster vaccine |
|
| Measure | Description | Time Frame |
|---|---|---|
| The incidence of herpes zoster at 12 months | During the 12-month follow-up period, the incidence of herpes zoster in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests. | 12 months |
| Incidence of herpes zoster | The proportion of lung cancer patients who developed herpes zoster during the study period. | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Survival rate | The survival rate of lung cancer patients within a specific time period (such as 1 year, 2 years, or 5 years). | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Lung cancer-related complications | Severity of herpes zoster and incidence of complications (e.g., postherpetic neuralgia) | 5 years |
| Length of hospital stay | Record the number of days of hospitalization for patients hospitalized due to herpes zoster |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Lung cancer patients can receive or not receive the herpes zoster vaccine
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D053061 | Herpes Zoster Vaccine |
| ID | Term |
|---|---|
| D019433 | Chickenpox Vaccine |
| D022283 | Herpesvirus Vaccines |
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
Not provided
Not provided
Not provided
Not provided
Not provided
| 5 years |
| Hospitalization rate | The proportion of patients hospitalized due to herpes zoster or other related complications. | 5 years |
| Immune response | The immune response (such as antibody levels) of patients after vaccination is evaluated through serological testing. | 5 years |
| Adverse reactions after vaccination | Observe whether patients who receive the herpes zoster vaccine experience adverse reactions after vaccination, such as fever, redness, swelling and pain at the injection site, headache, dizziness, etc. | 30 days |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D001688 |
| Biological Products |
| D045424 | Complex Mixtures |